Abstract
Sexual function is affected by treatment for both localized and advanced prostate cancer (PC). Erectile dysfunction (ED) has been studied in localized PC but rarely in advanced or metastatic disease. This study aimed to establish the prevalence of ED in patients with metastatic PC treated with androgen-deprivation therapy (ADT), and to determine the differences in the severity of ED in patients who have received different ADT: bilateral orchiectomy, hormonal therapy, androgen inhibitor, or their combination.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
